Clinical trials: Social Phobia
Social Anxiety Disorder, Anxiety Disorders
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
- Trial name
- NCT00273039
- Testing
- paroxetine
- Where
- 27 sites in United States, Argentina and 4 more
- Volunteers
- 242 people
- Sponsor
- GlaxoSmithKline
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Social Anxiety Disorder
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in adult men and women.
- Trial name
- NCT02622958
- Testing
- PH94B
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Social Anxiety Disorder
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of…
- Trial name
- AFFIRM-1 (NCT06510504)
- Testing
- 225 mg BNC210
- Where
- 21 sites in United States
- Volunteers
- 370 people
- Sponsor
- Bionomics Limited
Social Anxiety Disorder
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients…
- Trial name
- PREVAIL (NCT05193409)
- Testing
- 225 mg BNC210, 675 mg BNC210
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bionomics Limited
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Social Anxiety Disorder (Social Phobia), Social Anxiety
Efficacy and Safety of the Alena App as a Treatment for Social Anxiety Disorder
The present study is a randomised controlled trial that seeks to investigate the efficacy and safety of the Alena app as a treatment for social anxiety disorder.
- Conditions
- Social Anxiety Disorder (Social Phobia), Social Anxiety, Social Anxiety Disorder
- Trial name
- NCT05987969
- Testing
- "Alena" mobile application
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Aya Technologies Limited
Social Anxiety Disorder
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
This is a Phase 1b/2a clinical trial to evaluate the safety, tolerability, and efficacy of RLS103 (cannabidiol [CBD] inhaled dry powder) to relieve the anxiety induced by a public speaking challenge in adults with social anxiety…
- Trial name
- NCT05429788
- Testing
- Low dose RLS103, High dose RLS103
- Where
- 3 sites in United States
- Sponsor
- Receptor Life Sciences
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Bi-Polar Disorder, Autism Spectrum Disorder (ASD)
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
- Conditions
- Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder
- Trial name
- NCT07329673
- Testing
- Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Qbtech AB
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
- Trial name
- NCT00190879
- Testing
- Atomoxetine hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Social Phobia
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder.
- Trial name
- NCT00294346
- Testing
- AV608
- Where
- 15 sites in United States
- Volunteers
- 180 people
- Sponsor
- Avera Pharmaceuticals
Anxiety Disorders
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum.
- Trial name
- NCT00612859
- Testing
- levetiracetam
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Social Anxiety Disorder
CHI-902 for Treatment of Social Anxiety Disorder
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy…
- Trial name
- NCT04086342
- Testing
- CHI-902
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-1 (NCT04754802)
- Testing
- PH94B Nasal Spray
- Where
- 21 sites in United States
- Volunteers
- 224 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Phobia
Treatment Of Patients With Social Anxiety Disorder
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
- Trial name
- NCT00397722
- Testing
- GW876008, paroxetine
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 299 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder (SAD)
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-4 (NCT06615557)
- Testing
- Fasedienol Nasal Spray
- Where
- 26 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Phobia
Social Anxiety Disorder Study Of Paroxetine
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).
- Trial name
- NCT00318669
- Testing
- Paroxetine hydrochloride hydrate
- Where
- 16 sites in Japan
- Volunteers
- 390 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder (SAD)
A Study of NTX-1472 in Social Anxiety Disorder
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD).
- Trial name
- SOAR (NCT07323784)
- Testing
- NTX-1472
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newleos Therapeutics, Inc.